ATP5F1A

Across TCGA pan-cancer cohorts, ATP5F1A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATP5F1A data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ATP5F1A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5F1A expression acts as an unfavorable survival marker.

STAD, LIHC, and COAD are the cancer types where ATP5F1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.219	0.661	<.001	42	view →
LIHC	DFS	Median	All	0.153	0.558	.001	12	view →
COAD	OS	Median	All	0.485	0.802	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATP5F1A–STAD (DFS)

Open the STAD breakdown →